Selected research
Market Structure
Global Oncology & Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Oncology & Cancer Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Oncology & Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Oncology & Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Oncology & Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Oncology & Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Oncology & Cancer Drugs include Sanofi, Novartis, Roche, Lunan, Eli Lilly and Company, GuiZhou YiBai, AstraZeneca, QILU and LUYE, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Oncology & Cancer Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Oncology & Cancer Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Oncology & Cancer Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oncology & Cancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Oncology & Cancer Drugs Segment by Company
Sanofi
Novartis
Roche
Lunan
Eli Lilly and Company
GuiZhou YiBai
AstraZeneca
QILU
LUYE
HENGRUI
HANSOH
Oncology & Cancer Drugs Segment by Type
Platinum-based drugs
Hormone
Antimetabolite
Alkaloid drugs
Targeted drug
Other
Oncology & Cancer Drugs Segment by Application
Blood Cancer
Gastrointestinal Cancer
Breast Cancer
Prostate Cancer
Respiratory/Lung Cancer
Other
Oncology & Cancer Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology & Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncology & Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology & Cancer Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Oncology & Cancer Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology & Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Oncology & Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Oncology & Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Platinum-based drugs
- Hormone
- Antimetabolite
- Alkaloid drugs
- Targeted drug
- Other
Applications
- Blood Cancer
- Gastrointestinal Cancer
- Breast Cancer
- Prostate Cancer
- Respiratory/Lung Cancer
- Other
Companies covered
- Sanofi
- Novartis
- Roche
- Lunan
- Eli Lilly and Company
- GuiZhou YiBai
- AstraZeneca
- QILU
- LUYE
- HENGRUI
- HANSOH
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Oncology & Cancer Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Oncology & Cancer Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Oncology & Cancer Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Oncology & Cancer Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Oncology & Cancer Drugs Market Dynamics
- 2.1 Oncology & Cancer Drugs Industry Trends
- 2.2 Oncology & Cancer Drugs Industry Drivers
- 2.3 Oncology & Cancer Drugs Industry Opportunities and Challenges
- 2.4 Oncology & Cancer Drugs Industry Restraints
3 Oncology & Cancer Drugs Market by Manufacturers
- 3.1 Global Oncology & Cancer Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Oncology & Cancer Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Oncology & Cancer Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Oncology & Cancer Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Oncology & Cancer Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Oncology & Cancer Drugs Manufacturers, Product Type & Application
- 3.7 Global Oncology & Cancer Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Oncology & Cancer Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Oncology & Cancer Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Oncology & Cancer Drugs Tier 1, Tier 2, and Tier 3
4 Oncology & Cancer Drugs Market by Type
- 4.1 Oncology & Cancer Drugs Type Introduction
- 4.1.1 Platinum-based drugs
- 4.1.2 Hormone
- 4.1.3 Antimetabolite
- 4.1.4 Alkaloid drugs
- 4.1.5 Targeted drug
- 4.1.6 Other
- 4.2 Global Oncology & Cancer Drugs Sales by Type
- 4.2.1 Global Oncology & Cancer Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Oncology & Cancer Drugs Sales by Type (2021-2032)
- 4.2.3 Global Oncology & Cancer Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Oncology & Cancer Drugs Revenue by Type
- 4.3.1 Global Oncology & Cancer Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Oncology & Cancer Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Oncology & Cancer Drugs Revenue Market Share by Type (2021-2032)
5 Oncology & Cancer Drugs Market by Application
- 5.1 Oncology & Cancer Drugs Application Introduction
- 5.1.1 Blood Cancer
- 5.1.2 Gastrointestinal Cancer
- 5.1.3 Breast Cancer
- 5.1.4 Prostate Cancer
- 5.1.5 Respiratory/Lung Cancer
- 5.1.6 Other
- 5.2 Global Oncology & Cancer Drugs Sales by Application
- 5.2.1 Global Oncology & Cancer Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Oncology & Cancer Drugs Sales by Application (2021-2032)
- 5.2.3 Global Oncology & Cancer Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Oncology & Cancer Drugs Revenue by Application
- 5.3.1 Global Oncology & Cancer Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Oncology & Cancer Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Oncology & Cancer Drugs Revenue Market Share by Application (2021-2032)
6 Global Oncology & Cancer Drugs Sales by Region
- 6.1 Global Oncology & Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Oncology & Cancer Drugs Sales by Region (2021-2032)
- 6.2.1 Global Oncology & Cancer Drugs Sales by Region (2021-2026)
- 6.2.2 Global Oncology & Cancer Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Oncology & Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Oncology & Cancer Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Oncology & Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Oncology & Cancer Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Oncology & Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Oncology & Cancer Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Oncology & Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Oncology & Cancer Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Oncology & Cancer Drugs Revenue by Region
- 7.1 Global Oncology & Cancer Drugs Revenue by Region
- 7.1.1 Global Oncology & Cancer Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Oncology & Cancer Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Oncology & Cancer Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Oncology & Cancer Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Oncology & Cancer Drugs Revenue (2021-2032)
- 7.2.2 North America Oncology & Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Oncology & Cancer Drugs Revenue (2021-2032)
- 7.3.2 Europe Oncology & Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Oncology & Cancer Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Oncology & Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Oncology & Cancer Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Oncology & Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Sanofi
- 8.1.1 Sanofi Company Information
- 8.1.2 Sanofi Business Overview
- 8.1.3 Sanofi Oncology & Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Sanofi Oncology & Cancer Drugs Product Portfolio
- 8.1.5 Sanofi Recent Developments
- 8.2 Novartis
- 8.2.1 Novartis Company Information
- 8.2.2 Novartis Business Overview
- 8.2.3 Novartis Oncology & Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Novartis Oncology & Cancer Drugs Product Portfolio
- 8.2.5 Novartis Recent Developments
- 8.3 Roche
- 8.3.1 Roche Company Information
- 8.3.2 Roche Business Overview
- 8.3.3 Roche Oncology & Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Roche Oncology & Cancer Drugs Product Portfolio
- 8.3.5 Roche Recent Developments
- 8.4 Lunan
- 8.4.1 Lunan Company Information
- 8.4.2 Lunan Business Overview
- 8.4.3 Lunan Oncology & Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Lunan Oncology & Cancer Drugs Product Portfolio
- 8.4.5 Lunan Recent Developments
- 8.5 Eli Lilly and Company
- 8.5.1 Eli Lilly and Company Company Information
- 8.5.2 Eli Lilly and Company Business Overview
- 8.5.3 Eli Lilly and Company Oncology & Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Eli Lilly and Company Oncology & Cancer Drugs Product Portfolio
- 8.5.5 Eli Lilly and Company Recent Developments
- 8.6 GuiZhou YiBai
- 8.6.1 GuiZhou YiBai Company Information
- 8.6.2 GuiZhou YiBai Business Overview
- 8.6.3 GuiZhou YiBai Oncology & Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 GuiZhou YiBai Oncology & Cancer Drugs Product Portfolio
- 8.6.5 GuiZhou YiBai Recent Developments
- 8.7 AstraZeneca
- 8.7.1 AstraZeneca Company Information
- 8.7.2 AstraZeneca Business Overview
- 8.7.3 AstraZeneca Oncology & Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 AstraZeneca Oncology & Cancer Drugs Product Portfolio
- 8.7.5 AstraZeneca Recent Developments
- 8.8 QILU
- 8.8.1 QILU Company Information
- 8.8.2 QILU Business Overview
- 8.8.3 QILU Oncology & Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 QILU Oncology & Cancer Drugs Product Portfolio
- 8.8.5 QILU Recent Developments
- 8.9 LUYE
- 8.9.1 LUYE Company Information
- 8.9.2 LUYE Business Overview
- 8.9.3 LUYE Oncology & Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 LUYE Oncology & Cancer Drugs Product Portfolio
- 8.9.5 LUYE Recent Developments
- 8.10 HENGRUI
- 8.10.1 HENGRUI Company Information
- 8.10.2 HENGRUI Business Overview
- 8.10.3 HENGRUI Oncology & Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 HENGRUI Oncology & Cancer Drugs Product Portfolio
- 8.10.5 HENGRUI Recent Developments
- 8.11 HANSOH
- 8.11.1 HANSOH Company Information
- 8.11.2 HANSOH Business Overview
- 8.11.3 HANSOH Oncology & Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 HANSOH Oncology & Cancer Drugs Product Portfolio
- 8.11.5 HANSOH Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Oncology & Cancer Drugs Value Chain Analysis
- 9.1.1 Oncology & Cancer Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Oncology & Cancer Drugs Production Mode & Process
- 9.2 Oncology & Cancer Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Oncology & Cancer Drugs Distributors
- 9.2.3 Oncology & Cancer Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst